Regular Article
Significance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and Its Inhibition by the Antibody

https://doi.org/10.1006/bbrc.1993.1955Get rights and content

Abstract

Angiogenesis is essential for successful tumor growth in vivo. There is a hypothesis that tumors secrete a putative tumor angiogenic factor (TAF) to facilitate blood vessel formations. Although several endothelial growth factors have been reported, it remains unclear whether these factors function as TAF in vivo. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) is a vascular endothelial mitogen that can increase blood vessel permeability. We have established a cell line (HeLa/v5), which secretes VEGF/VPF, by transfection of human VEGF/VPF cDNA. HeLa/v5 showed higher angiogenic activity, taken/planted ratio and tumor growth rate than the control transformant (HeLa/c), when they were implanted to nude mice. Administration of a polyclonal antibody, which neutralizes the mitogenic activity of VEGF/VPF in vitro, to the tumor implanted nude mice suppressed the in vivo growth of HeLa/v5. Furthermore, all 8 tumor cell lines we tested secrete VEGF/VPF into culture media. Our findings indicate that VEGF/VPF is a tumor angiogenic factor.

References (0)

Cited by (163)

  • Age-Related Macular Degeneration: An Overview

    2014, Handbook of Nutrition, Diet and the Eye
  • Refractive errors and age-related macular degeneration: A systematic review and meta-analysis

    2013, Ophthalmology
    Citation Excerpt :

    Vascular endothelial growth factor plays a key role in AMD pathophysiology.5 Vascular endothelial growth factor is a key regulator of angiogenesis, and withdrawal or interference with its function leads to cessation of vascular growth and neovascular regression.31 Recent findings indicated that the intraocular concentration of VEGF decreased significantly with increasing myopia and increasing AL,32 which may explain why myopic eyes have a lower prevalence of AMD because decreasing intraocular concentration of VEGF could lower the risk of AMD.

  • Age-related macular degeneration

    2012, The Lancet
    Citation Excerpt :

    More recently, attention has been focused on the function of VEGF in light of its role as a therapeutic target.39 VEGF is a key regulator of angiogenesis, and withdrawal or interference with its function leads to cessation of vascular growth and neovascular regression.40 VEGF expression has been shown in experimental choroidal neovascularisation, and shown to induce choroidal neovascularisation growth in animals.

  • Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome

    2009, Cancer Letters
    Citation Excerpt :

    Vascular endothelial growth factors (VEGF) and its receptors are the key players in angiogensis. By binding to its receptors, VEGFR-1 and VEGFR-2, this proangiogenic factor can trigger a series of downstream signaling cascades and facilitate angiogenesis [36,37]. It has been found that VEGF and VEGFRs were overexpressed in ovarian carcinoma when compared with the benign ovarian tumours and normal OSE cells [32].

View all citing articles on Scopus
View full text